Clinical Trial Update: A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing oral AZD9833 (camizestrant) with intramuscular fulvestrant in postmenopausal women with advanced ER-positive HER2-negative breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AZD9833 (AZD9833)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced ER-Positive HER2-Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-12-12